Next, AML cell lines MV4;11, Kasumi-1, and KG1α were treated with NRF2 inhibitor ML385 alone, a GPX4 inhibitor (FIN56 or RSL3) alone, or ML385 combined with a GPX4 inhibitor. This evidence concerns the gene NFE2L2 and acute myeloid leukemia.